Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.6
3.6
Journals
Diagnostics
Special Issues
New Insights into Diagnosis and Prevention of Hepatocellular Carcinoma (HCC)
share announcement

New Insights into Diagnosis and Prevention of Hepatocellular Carcinoma (HCC)

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 2283

Special Issue Editors

Dr. Hiroko Naganuma

E-Mail Website
Guest Editor
Department of Gastroenterology, Yokote Municipal Hospital, Negishi-cho 5-31, Yokote 013-8602, Japan
Interests: hepatocellular carcinoma (HCC); precancerous lesion; liver cirrhosis; screening system; diagnosis; prevention; liver tumor; liver
Special Issues, Collections and Topics in MDPI journals
Dr. Masahiro Ogawa

E-Mail Website
Guest Editor
Department of Gastroenterology, Nihon University Hospital, Chiyoda Ku, 1-6 Kanda, Tokyo 1018309, Japan
Interests: hepatocellular carcinoma; liver failure; gastroenterology; diagnostic imaging; ultrasonic diagnosis
Dr. Hidekatsu Kuroda

E-Mail Website
Guest Editor
Division of Hepatology, Department of Internal Medicine, Iwate Medical University, Uchimaru 19-1, Morioka, Iwate 020-8505, Japan
Interests: hepatocellular carcinoma; liver; medical image analysis; elastography; ultrasonics; interventional ultrasonography; microbubbles

Special Issue Information

Dear Colleagues, 

Hepatocellular carcinoma (HCC) ranks fifth in cancer incidence and third in cancer mortality worldwide. Hepatitis virus, alcoholism, and NASH have emerged as key factors for HCC development. However, HCC occurrence remains unpredictable, and many issues regarding its natural history are still elusive. The goal of this Special Issue is to discuss the diagnosis and prevention of HCC from many points of view, including HCC without precancerous condition, combined hepatocholangiocarcinoma, cholangiolocellular carcinoma, AI diagnosis of HCC, and new screening systems for HCC. It seems to be extremely valuable to have a thorough understanding of HCC from many different angles, in order to provide new hints for upcoming research.   

Dr. Hiroko Naganuma
Dr. Masahiro Ogawa
Dr. Hidekatsu Kuroda
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hepatocellular carcinoma (HCC)
  • precancerous lesion
  • liver cirrhosis
  • screening system
  • diagnosis
  • prevention
  • liver tumor
  • liver

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

17 pages, 4637 KiB  
Review
Hepatocellular Carcinoma in Non-Fibrotic Liver: A Narrative Review
by Hiroko Naganuma and Hideaki Ishida
Diagnostics 2023, 13(22), 3426; https://doi.org/10.3390/diagnostics13223426 - 10 Nov 2023
Viewed by 737
Abstract
Hepatocellular carcinoma (HCC) in a non-fibrotic liver (F0) is considered to be rare, and there is a marked paucity of studies in the literature on this HCC type. A review of the literature shows some important clinical and tumor characteristics: (a) it occurs [...] Read more.
Hepatocellular carcinoma (HCC) in a non-fibrotic liver (F0) is considered to be rare, and there is a marked paucity of studies in the literature on this HCC type. A review of the literature shows some important clinical and tumor characteristics: (a) it occurs mainly in young female and elder male patients; (b) clinically, under normal hepatic function, alpha-fetoprotein level is often normal, and there are no risk factors; (c) associated with metabolic disease; (d) macroscopically, single large lesions are noted; and (e) microscopically, the lesions are well-differentiated and encapsulated. Radiological imaging results are straightforward, showing arterial hyperenhancement and later wash-out. The combined use of B-mode and contrast-enhanced (CE) ultrasound (US) is the most reliable and cost-effective diagnostic method. Few peri-and post-operative complications are noted and 5-year survival is not inferior to patients with HCC on fibrosis liver despite the lesion’s large size. Most clinicians believe that HCC is unlikely to occur if patients have no symptoms and normal hepatic function. Although detailed clinical data are very limited, we expect that this review will help to improve the clinical management of HCC in non-fibrotic livers. Full article
(This article belongs to the Special Issue New Insights into Diagnosis and Prevention of Hepatocellular Carcinoma (HCC))
►▼ Show Figures

Figure 1

22 pages, 12801 KiB  
Review
Predicting Outcome after Percutaneous Ablation for Early-Stage Hepatocellular Carcinoma Using Various Imaging Modalities
by Ryo Shimizu, Yoshiyuki Ida and Masayuki Kitano
Diagnostics 2023, 13(19), 3058; https://doi.org/10.3390/diagnostics13193058 - 26 Sep 2023
Viewed by 971
Abstract
Percutaneous ablation is a low-invasive, repeatable, and curative local treatment that is now recommended for early-stage hepatocellular carcinoma (HCC) that is not suitable for surgical resection. Poorly differentiated HCC has high-grade malignancy potential. Microvascular invasion is frequently seen, even in tumors smaller than [...] Read more.
Percutaneous ablation is a low-invasive, repeatable, and curative local treatment that is now recommended for early-stage hepatocellular carcinoma (HCC) that is not suitable for surgical resection. Poorly differentiated HCC has high-grade malignancy potential. Microvascular invasion is frequently seen, even in tumors smaller than 3 cm in diameter, and prognosis is poor after percutaneous ablation. Biopsy has a high risk of complications such as bleeding and dissemination; therefore, it has limitations in determining HCC tumor malignancy prior to treatment. Advances in diagnostic imaging have enabled non-invasive diagnosis of tumor malignancy. We describe the usefulness of ultrasonography, computed tomography, magnetic resonance imaging, and 18F-fluorodeoxyglucose positron emission tomography for predicting outcome after percutaneous ablation for HCC. Full article
(This article belongs to the Special Issue New Insights into Diagnosis and Prevention of Hepatocellular Carcinoma (HCC))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop